PNAS:日本科学家开发出糖尿病治疗疫苗

2014-03-19 佚名 新华网

糖尿病患者为了降低血糖值,需要持续服用药物。 日前,日本科学家在PNAS上报告称,他们新开发的治疗疫苗可成功降低血糖值,且效果能够持续两三个月,省去了需要经常服药的麻烦。 人们进食后,小肠释放的激素胰高血糖素样肽-1(GLP-1)会促进胰腺分泌胰岛素,从而降低血糖值。但是,血液中微量存在的二肽基肽酶-4(DPP-4)则会分解 GLP-1,从而导致血糖升高。开发阻碍 DPP-4 发挥作用的抑制剂

糖尿病患者为了降低血糖值,需要持续服用药物。

日前,日本科学家在PNAS上报告称,他们新开发的治疗疫苗可成功降低血糖值,且效果能够持续两三个月,省去了需要经常服药的麻烦。

人们进食后,小肠释放的激素胰高血糖素样肽-1(GLP-1)会促进胰腺分泌胰岛素,从而降低血糖值。但是,血液中微量存在的二肽基肽酶-4(DPP-4)则会分解 GLP-1,从而导致血糖升高。开发阻碍 DPP-4 发挥作用的抑制剂一直是治疗糖尿病的一个主要方向。

日本大阪大学教授中神启德领导的研究小组制作了针对 DPP-4 的疫苗,并通过喂食高脂肪食物,使实验鼠患上糖尿病。随后每隔两周时间,他们给患病实验鼠注射1次疫苗,共注射了 3 次。结果显示,实验鼠体内产生了抗体,DPP-4 在血液中的浓度下降,GLP-1 和胰岛素的浓度则上升,显示疫苗与现有的 DPP-4 抑制剂一样,能够降低血糖值,改善糖尿病症状。

由于这种疫苗的效果能够持续 2 至 3 个月,所以省去了需要经常服药的麻烦,也不用经常提醒自己按时服用药物。

研究人员表示,这种疫苗有望成为治疗糖尿病的新方法,并准备在5年后开展确认其安全性和效果的临床试验。

原始出处:

Zhengda Pang, Hironori Nakagami, Mariana K. Osako, Hiroshi Koriyama, Futoshi Nakagami,Hideki Tomioka, Munehisa Shimamura, Hitomi Kurinami, Yoichi Takami, Ryuichi Morishita,and Hiromi Rakugi. Therapeutic vaccine against DPP4 improves glucose metabolism in mice. PNAS, March 17, 2014; doi:10.1073/pnas.1322009111

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1989919, encodeId=972419899195e, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Fri Dec 12 09:23:00 CST 2014, time=2014-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855523, encodeId=055a1855523be, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon May 19 12:23:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775010, encodeId=dfdf1e75010d4, content=<a href='/topic/show?id=5e9a6094488' target=_blank style='color:#2F92EE;'>#本科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60944, encryptionId=5e9a6094488, topicName=本科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df2b38746341, createdName=wushaoling, createdTime=Mon Aug 11 22:23:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294168, encodeId=102a1294168bb, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Mar 21 01:23:00 CST 2014, time=2014-03-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1989919, encodeId=972419899195e, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Fri Dec 12 09:23:00 CST 2014, time=2014-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855523, encodeId=055a1855523be, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon May 19 12:23:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775010, encodeId=dfdf1e75010d4, content=<a href='/topic/show?id=5e9a6094488' target=_blank style='color:#2F92EE;'>#本科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60944, encryptionId=5e9a6094488, topicName=本科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df2b38746341, createdName=wushaoling, createdTime=Mon Aug 11 22:23:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294168, encodeId=102a1294168bb, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Mar 21 01:23:00 CST 2014, time=2014-03-21, status=1, ipAttribution=)]
    2014-05-19 drwjr
  3. [GetPortalCommentsPageByObjectIdResponse(id=1989919, encodeId=972419899195e, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Fri Dec 12 09:23:00 CST 2014, time=2014-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855523, encodeId=055a1855523be, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon May 19 12:23:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775010, encodeId=dfdf1e75010d4, content=<a href='/topic/show?id=5e9a6094488' target=_blank style='color:#2F92EE;'>#本科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60944, encryptionId=5e9a6094488, topicName=本科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df2b38746341, createdName=wushaoling, createdTime=Mon Aug 11 22:23:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294168, encodeId=102a1294168bb, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Mar 21 01:23:00 CST 2014, time=2014-03-21, status=1, ipAttribution=)]
    2014-08-11 wushaoling
  4. [GetPortalCommentsPageByObjectIdResponse(id=1989919, encodeId=972419899195e, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Fri Dec 12 09:23:00 CST 2014, time=2014-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855523, encodeId=055a1855523be, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon May 19 12:23:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775010, encodeId=dfdf1e75010d4, content=<a href='/topic/show?id=5e9a6094488' target=_blank style='color:#2F92EE;'>#本科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60944, encryptionId=5e9a6094488, topicName=本科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df2b38746341, createdName=wushaoling, createdTime=Mon Aug 11 22:23:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294168, encodeId=102a1294168bb, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Mar 21 01:23:00 CST 2014, time=2014-03-21, status=1, ipAttribution=)]

相关资讯

内外科协作治疗糖尿病的优势与互补

目前实施代谢手术的临床模式大多是由外科独立招募患者后进行手术治疗和术后随访,但存在缺乏术前对糖尿病系统评估、术式和手术具体参数的选择未体现个体化、术后随访注重早期而忽视中远期管理等问题。糖尿病涉及多种代谢紊乱,往往伴有多系统并发症,其本质为内科疾病,诊断与治疗的原则仍应遵循其特有规律。手术治疗只是其中一种治疗手段,糖尿病的综合控制需要多学科专业团队参与,对治疗流程进行科学整

Nature:研究发现二甲双胍抗癌的直接证据

近年来,一类被称作为双胍类的抗糖尿病药物证实与某些抗癌特性有关联。一些回顾性研究表明,广泛应用的糖尿病药物二甲双胍可以使某些癌症患者受益。尽管存在这一有趣的关联,人们一直以来却并不清楚二甲双胍是如何发挥它的抗癌效应的,更重要的是它会在哪些患者中发挥这一效应。 现在,来自麻省理工怀特黑德研究所(Whitehead, MIT)的科学家们开始解开这一谜团,确定了一条使得癌细胞能够在低葡萄糖环境中存活的

Lancet Diab & Endo:心衰应该成为糖尿病药物临床试验的一项重点要求

研究人员表示,糖尿病药物临床试验应将检测心衰作为一项重要的结局试验。心衰住院治疗是糖尿病一项最常见并且是可预见的重要并发症,应该作为临床试验的一个终点,格拉斯哥大学医学博士John McMurray与其同事在The Lancet Diabetes & Endocrinology上的一篇评述文章中这样写道。 “我们认为在降糖新药的心血管结局临床试验中应该进行心衰的系统性评价,要么将其作

CDS发布《基于胰高血糖素样肽-1降糖药物的临床应用共识》

中华医学会糖尿病学分会(CDS)在《中华糖尿病杂志》2014年1月第6卷第1期发布了《基于胰高血糖素样肽-1降糖药物的临床应用共识》。该共识从肠促胰素类药物的发现和发展、作用机制、药物分类及临床应用等方面进行阐述,旨在便于临床医师全面和快速地了解此类药物的基本知识以及在我国的临床研究和应用情况。共识下载:基于胰高血糖素样肽-1降糖药物的临床应用共识

Diabetologia:糖尿病增加癌症死亡风险

丹麦Steno 糖尿病研究中心团队研究发现,糖尿病合并癌症患者死亡风险高于血糖水平正常的癌症患者。 “相比无糖尿病的癌症患者,接受胰岛素治疗的患者治疗结局不容乐观。” 该文章近期发表在Diabetologia杂志,现有的证据表明血糖强化治疗强度越大,肿瘤患者相关并发症严重程度越高,导致患者的低生存率。 该研究团队的首席专家Ranc教授就该发现提出了申明:“糖尿病